Esophageal Cancer Clinical Trials in Detroit, Michigan

4 studies are recruiting for esophageal cancer in Detroit, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Karmanos Cancer Institiute, Detroit, Michigan
    Locations
    26 in total
    Run by
    SystImmune Inc.

    See if you can join NCT06293898 on ClinicalTrials.gov

  2. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

    This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Karmanos Cancer Institute, Detroit, Michigan
    Locations
    54 in total
    Run by
    Merus B.V.

    See if you can join NCT03526835 on ClinicalTrials.gov

  3. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
    Locations
    28 in total
    Run by
    Jazz Pharmaceuticals

    See if you can join NCT06695845 on ClinicalTrials.gov

  4. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Karmanos Cancer Institute, Detroit, Michigan
    Locations
    27 in total
    Run by
    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.